These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2699722)

  • 21. [Evidence-based planning: the case of mass screening for colorectal cancer in the Lazio region of Italy].
    Federici A; Borgia P; Guasticchi G
    Ann Ig; 2005; 17(4):313-22. PubMed ID: 16156391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for colorectal cancer on the front line.
    Lemon SC; Zapka JG; Estabrook B; Erban S; Luckmann R
    Am J Gastroenterol; 2003 Apr; 98(4):915-23. PubMed ID: 12738477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for colorectal cancer.
    Mandel JS
    Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. French colorectal cancer screening pilot programme: results of the first round.
    Goulard H; Boussac-Zarebska M; Ancelle-Park R; Bloch J
    J Med Screen; 2008; 15(3):143-8. PubMed ID: 18927097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low priority main reason not to participate in a colorectal cancer screening program with a faecal occult blood test.
    van Rijn AF; van Rossum LG; Deutekom M; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    J Public Health (Oxf); 2008 Dec; 30(4):461-5. PubMed ID: 18716047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of colorectal cancer stage among HMO members targeted for screening.
    Myers RE; Murray J; Weinberg D; McGrory G; Wolf T; Caveny J; Hanchak N; Schlackman N; Comis R
    Arch Intern Med; 1997 Sep; 157(17):2001-6. PubMed ID: 9308512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Better acceptance of Fecal Occult Blood Test (FOBT) for colorectal cancer screening during hospitalization.
    Keller R; Schätzle A; Flieger D; Christl SU; Fischbach W
    Z Gastroenterol; 2003 Jul; 41(7):655-8. PubMed ID: 12858236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal occult blood testing: comparative evaluation of a two-hole versus a three-hole single slide test.
    Porschen R; Kruis W; Strohmeyer G
    Hepatogastroenterology; 1993 Apr; 40(2):191-3. PubMed ID: 8509054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain).
    Peris M; Espinàs JA; Muñoz L; Navarro M; Binefa G; Borràs JM;
    J Med Screen; 2007; 14(2):81-6. PubMed ID: 17626707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Views of a general population on mass screening for colorectal cancer: the Burgundy Study.
    Arveux P; Durand G; Milan C; Bedenne L; Lévy D; Doan BD; Faivre J
    Prev Med; 1992 Sep; 21(5):574-81. PubMed ID: 1438107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceptability of opportunistic screening for occult gastrointestinal blood loss.
    Hobbs FD; Cherry RC; Fielding JW; Pike L; Holder R
    BMJ; 1992 Feb; 304(6825):483-6. PubMed ID: 1547423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study.
    Mandel JS; Bond JH; Bradley M; Snover DC; Church TR; Williams S; Watt G; Schuman LM; Ederer F; Gilbertsen V
    Gastroenterology; 1989 Sep; 97(3):597-600. PubMed ID: 2666251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A general practice-based recruitment strategy for colorectal cancer screening.
    Harris MA; Byles JE; Cockburn J; D'Este C
    Aust N Z J Public Health; 2000 Aug; 24(4):441-3. PubMed ID: 11011475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemoccult II Screening for Bowel Cancer: Will Family Practice Patients Accept It?
    Sangster JF; Gerace TM; Bass MJ
    Can Fam Physician; 1986 Feb; 32():289-95. PubMed ID: 21267262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost/Benefit of hemoccult test.
    McAuley RG; Josiukas A; Kronitz N; Loukras C; Macfarlane G; Plach N; Yates J
    Can Fam Physician; 1983 Feb; 29():206. PubMed ID: 21283312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.